Sign In
Buy SRPT
$14.86
-0.700 (-4.50%)
At Close: Jul 31, 2026
Sarepta's (SRPT) DMD Gene Therapy BLA Gets FDA Priority Review
05:07pm, Tuesday, 29'th Nov 2022 Zacks Investment Research
The FDA accepts Sarepta's (SRPT) regulatory filing seeking accelerated approval for SRP-9001, a gene therapy for DMD indication. A final decision is expected by May 2023.
Sarepta's (SRPT) DMD Gene Therapy BLA Gets FDA Priority Review
01:32pm, Tuesday, 29'th Nov 2022
The FDA accepts Sarepta's (SRPT) regulatory filing seeking accelerated approval for SRP-9001, a gene therapy for DMD indication. A final decision is expected by May 2023.
Sarepta Surges As It Nears The Finish Line With A Muscular Dystrophy Gene Therapy
09:28am, Monday, 28'th Nov 2022
The FDA said Monday it will perform a speedy review of Sarepta Therapeutics' muscular dystrophy gene therapy, and SRPT stock jumped. The post Sarepta Surges As It Nears The Finish Line With A Muscular
Sarepa expected to get FDA decision on Duchenne treatment by May 29
08:35am, Monday, 28'th Nov 2022
Shares of Sarepta Therapeutics Inc. SRPT, -0.15% were up 4.6% in premarket trading on Monday after the company said U.S. regulators accepted its application for accelerated approval of SRP-9001, its e
Sarepta Therapeutics to Present at the Evercore ISI HealthCONx Conference
01:30pm, Wednesday, 23'rd Nov 2022 GlobeNewswire Inc.
CAMBRIDGE, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will
Sarepta Therapeutics to Present at the Evercore ISI HealthCONx Conference
08:30am, Wednesday, 23'rd Nov 2022
CAMBRIDGE, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that senior management will pa
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
11:20am, Tuesday, 15'th Nov 2022 Zacks Investment Research
Sector ETF report for FBT
Should iShares Morningstar SmallCap ETF (ISCB) Be on Your Investing Radar?
11:20am, Friday, 11'th Nov 2022 Zacks Investment Research
Style Box ETF report for ISCB
Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?
11:20am, Wednesday, 09'th Nov 2022 Zacks Investment Research
Smart Beta ETF report for FXH
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
11:20am, Wednesday, 09'th Nov 2022 Zacks Investment Research
Smart Beta ETF report for FBT
Should iShares Morningstar SmallCap Growth ETF (ISCG) Be on Your Investing Radar?
11:20am, Tuesday, 08'th Nov 2022 Zacks Investment Research
Style Box ETF report for ISCG
Sarepta (SRPT) Q3 Loss Wider-Than-Expected, Sales Lag Estimates
05:25pm, Thursday, 03'rd Nov 2022 Zacks Investment Research
Sarepta's (SRPT) reports dismal third-quarter 2022 results. The company misses estimates for earnings and sales. Shares decline in after-market trading post the announcement.
Sarepta (SRPT) Q3 Loss Wider-Than-Expected, Sales Lag Estimates
03:04pm, Thursday, 03'rd Nov 2022
Sarepta's (SRPT) reports dismal third-quarter 2022 results. The company misses estimates for earnings and sales.
Analyst Ratings for Sarepta Therapeutics
01:23pm, Thursday, 03'rd Nov 2022 Benzinga
Within the last quarter, Sarepta Therapeutics (NASDAQ:SRPT) has observed the following analyst ratings:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
2
2
0
0
Sarepta Therapeutics (SRPT) Q3 2022 Earnings Call Transcript
06:00am, Thursday, 03'rd Nov 2022 The Motley Fool
SRPT earnings call for the period ending September 30, 2022.
